Nationwide Children's Hospital designated as Wellstone Muscular Dystrophy Cooperative Research Center

Nationwide Children's Hospital designated as Wellstone Muscular Dystrophy Cooperative Research Center: "A $7 million grant from the National Institutes of Health (NIH) will help researchers at Nationwide Children's Hospital translate new scientific findings and technological developments into novel treatments for the muscular dystrophies. The grant designates Nationwide Children's Hospital as a Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, one of three national award recipients in 2010."

Google Reader (1)

Google Reader (1): "CAMBRIDGE, Mass. -- Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength."

Parent Project Muscular Dystrophy: Coach to Cure MD

Parent Project Muscular Dystrophy:: "Today is a critical day for Duchenne. Actually every day is a critical day for Duchenne. And we know that often it may seem we are coming to you, the Duchenne community, to get involved and to take part in numerous things. That is because no one can do everything...We need your help in this fight to end Duchenne. We need you to join Coach To Cure MD.

By joining our team, by participating in even the smallest way, you help:

push critical research forward;
develop standards of care to ensure that your child is cared for properly; and
remind decision-makers in Washington that our boys count - that their lives matter.
Participating doesn't have to hard, it doesn't have to be time consuming. But we must work as a team if we are going to see success in our sons' lifetimes."

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation: "Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength."